Sesen Bio (NASDAQ:SESN) has chosen Cardinal Health to be its exclusive third-party logistics (3PL) and specialty pharmaceutical distribution services provider related to Vicineum’s commercial distribution in the US.
Cardinal Health to offer 3PL services to Sesen
Vicineum is the company’s lead program called VB4-845, which is currently in a follow-in stage of third phase registration study for treating high-risk BCG-unresponsive NMIBC. In December last year, Sesen Bio initiated a Biologics License Application submission for Vicineum to the US FDA under a rolling review.
Cardinal Health is expected to offer comprehensive end-to-end 3PL, specialty pharmaceutical distribution services, and order-to-cash management to Sesen Bio, supporting US commercialization of Vicineum. The LaVergne, Tennessee-based Cardinal Health 3PL Services facility is strategically situated in the same area as Sesen Bio’s specialty pharmaceutical distribution operations. It is also close to the FedEx shipping hub, simplifying and mitigating risks in the supply chain operations. Cardinal Health is very experienced in urology, and currently, it serves more than 10,000 specialty clinical in the US. It has relationships with over 1,600 Urologists in the US, and this will be of massive value to Sesen Bio.
Sesen to leverage Cardinal Health’s network of urology clinics
Thomas Cannell, the CEO and President of Sesen, said that Cardinal Health is a leading warehouse operator and specialty pharmaceuticals distributor with an extensive oncology portfolio that includes Uro-oncology. He stated that the partnership with Cardinal health for 3PL and specialty pharmaceutical supply services will offer Sesen an integrated distribution solution. The Cardinal Health partnership, in addition to Baxter and Fujifilm, completes the selection of leading supply chain partners supporting the commercial distribution of Vicineum. Thomas stated that they are confident that by mid-2021, the supply chain will be ready to support the commercial launch of Vicineum.
Vicineum is Sesen’s lead product candidate, a locally administered fusion protein under development to treat high-risk non-muscle invasive bladder cancers. The product comprises a recombinant fusion protein targeting epithelial cell adhesion molecule antigens in the tumor cells surface to deliver a strong protein payload, Pseudomonas Exotoxin A.
